A Phase Ib, Multi-center, Two Parallel Group, Open-label, Drug-drug Interaction Study to Assess the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients With Advanced Solid Tumors

Inclusion Criteria:

- Adults

- Patients with cytopathologically or histopathologically confirmed diagnosis of an
advanced solid tumor which has progressed despite standard therapy, or for which no
standard therapy exists.

- Protocol-defined renal , liver and bone marrow function

Exclusion Criteria:

- CNS (Central Nervous System) tumors as well as history of brain metastases

- Systemic anticancer treatment (including biologic therapy/antibodies) within 2 weeks
before first dose of study treatment (6 weeks for nitrosourea, mitomycin, and
monoclonal antibodies).

- Radiation therapy within 4 weeks before first dose

- Investigational agents within 4 weeks before start of study therapy

- Patients with known allergy/hypersensitivity to warfarin or bupropion and/or related
compounds

- Patients with a history of/or active bleeding disorders

- Patients receiving treatment with vitamin K, Coumadin or other agents containing
warfarin and heparin. Heparin flush to maintain patency of a central venous access
device is allowed.

- Patients receiving treatment with bupropion.

- Patients who have neuromuscular disorders that are associated with elevated CK
(Creatine phosphokinase) (e.g., inflammatory myopathies, muscular dystrophy,
amyotrophic lateral sclerosis, spinal muscular atrophy).

- Known diagnosis of human immunodeficiency virus (HIV), Hepatitis B or C (testing is
not mandatory for study entry)

- Patients currently receiving systemic corticosteroids Other protocol-defined
inclusion/exclusion criteria may apply